Israel - hebraico - Ministry of Health

לבונה כימיקלים חברה בעמ - חפיפת שיער

Israel - hebraico - Ministry of Health

לבונה כימיקלים חברה בעמ - טיפוח השיער

Israel - hebraico - Ministry of Health

cts ltd - ulipristal acetate - טבליה - ulipristal acetate 30 mg - ulipristal - ulipristal - emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure.

Israel - hebraico - Ministry of Health

cts ltd - ulipristal acetate - טבליה - ulipristal acetate 30 mg - ulipristal

Israel - hebraico - Ministry of Health

cts ltd - ulipristal acetate - טבליה - ulipristal acetate 30 mg - ulipristal

Israel - hebraico - Ministry of Health

eisai israel ltd., israel - perampanel as anhydrous - תרחיף - perampanel as anhydrous 0.5 mg / 1 ml - perampanel

Israel - hebraico - Ministry of Health

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 2 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

Israel - hebraico - Ministry of Health

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 4 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

Israel - hebraico - Ministry of Health

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 6 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

Israel - hebraico - Ministry of Health

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 8 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.